In a large case-control multicenter study, treatment failure was more likely to occur among women with SLE or other autoimmune diseases, history of both thrombosis and pregnancy complications and triple positivity for aPL.19A recent multicenter cohort study confirmed that the presence of autoimmune disease, complement consumption and previous thrombosis were risk factors for the occurrence of adverse pregnancy outcomes in APS, regardless of the treatment approach used to prevent these outcomes.20 This evidence concerns the gene FASLG and systemic lupus erythematosus.